Somatostatinoma Active Not Recruiting Phase 2 Trials for Regorafenib (DB08896)

Also known as: Somatostatinomas

IndicationStatusPhase
DBCOND0000820 (Somatostatinoma)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02259725Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine TumorsTreatment